Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
06/01/18
Seres Therapeutics to Present at Two Upcoming June Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences: Jefferies 2018 Global Healthcare Conference: a corporate overview will be presented on Wednesday, June 6 at 4:30 p.m. ET in New York, NY. Goldman Sachs 39th Annual Global Healthcare Conference: a corporate overview will be ... 
05/17/18
Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that the Company will host a Microbiome R&D Day on Thursday, May 24, 2018, from 8:00 a.m.–10:30 a.m. ET in New York, NY. The event will feature presentations from Seres management and leading academic subject matter experts on the microbiome as a new therapeutic target, with a focus on the Seres pipeline and the opportunity for ... 
05/09/18
Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates
– Preclinical data provide mechanistic insights related to the potency of microbiome therapeutics to augment immuno-oncology treatments; initiation of clinical study in metastatic melanoma planned for later this year – – FDA dialogue ongoing to support development of SER-287 for Ulcerative Colitis; Company plans to initiate clinical trial in mid-2018 – – Company to host Microbiome R&D Day on May 24 in New York City – ... 
EventsMore
Webcast ImageWebcast
Seres Therapeutics, Inc. at the Goldman Sachs 39th Annual Global Healthcare Conference  (Replay)
06/13/18 at 9:20 a.m. PT
Seres Therapeutics, Inc. at the Goldman Sachs 39th Annual Global Healthcare Conference
Wednesday, June 13, 2018 9:20 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Download DocumentationCorporate Presentation

There are currently no upcoming events scheduled.
Stock Quote
NASDAQ:MCRB
$8.88
 + 0.14 (1.60%)
06/19/18 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.